peripheral vertigo. Other peripheral vertigo
Conditions
Interventions
Intervention 1: Intervention group: The first group receives 8 mg of betahistine three times a day. Intervention 2: Intervention group: The second group received 25 mg of cinnarizine three times a day
Sponsors
Vice chancellor for research, Shahrekord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18-65 years old Having symptoms of vertigo for at least two months Non-sensitivity to cinnarizine and betahistine Natural Signs and Natural Nerve Findings Failure to receive vertigo control drugs at least 7 days before There is no evidence of the causes of central vertigo in a CT scan performed by a patient before the start of the study
Exclusion criteria
Exclusion criteria: Patients with abnormal vital signs, kidney failure, liver disease, heart disease, active stomach ulcer disease or diabetes Patients with ulcerative diagnosis of vertigo with central causes Brain traumatic brain injury Concomitant use of hypertension drugs such as thiazide, antihistamines, corticosteroids and calcium channel antagonists. Patients who are being treated for benzodiazepines for any reason Patients who have received anti-vertigo during the last week The sensitivity of the drug to cinnarizine and betahistine Those who are pregnant or breastfeeding People who are not satisfied with the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of vertigo attacks. Timepoint: Patients will be asked one week after the start of the study and 8 weeks after the start of the study. Method of measurement: vertigo symptom scale questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadhosein Saffari
Shahre-kord University of Medical Sciences
Outcome results
None listed